Journal
BIOLOGICAL PSYCHIATRY
Volume 72, Issue 11, Pages 950-956Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2012.05.032
Keywords
Amphetamines; clinical trial; cocaine dependence; topiramate; treatment; substance dependence
Categories
Funding
- National Institute on Drug Abuse Grant [R01 DA022217, K23 DA021209, K24 029647, K24 DA022412]
- Eli Lilly and Company
- UCB Pharma Inc
- Shire Pharmaceuticals Group
- AstraZeneca
- OrthoMcNeil Pharmaceutical Inc.
- National Institute on Drug Abuse
- Medical Research Council [MC_U120036861] Funding Source: researchfish
- MRC [MC_U120036861] Funding Source: UKRI
Ask authors/readers for more resources
Background: Cocaine dependence is a substantial public health problem, yet there are no clearly effective medication treatments. Amphetamine and topiramate have both shown promise for the treatment of cocaine dependence in preclinical and early-stage clinical studies. Methods: Eighty-one cocaine-dependent adults were randomized to receive a combination of extended-release mixed amphetamine salts (MAS-ER) and topiramate or placebo for 12 weeks under double-blind conditions. MAS-ER doses were titrated over 2 weeks to a maximum dose of 60 mg daily, and topiramate doses were titrated over 6 weeks to a maximum dose of 150 mg twice daily. All participants received a supportive behavioral intervention. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence as measured by urine toxicology confirmed self-report. Results: The overall proportion of participants who achieved 3 consecutive weeks of abstinence was larger in the extended-release mixed amphetamine salts and topiramate group (33.3%) than in placebo group (16.7%). There was a significant moderating effect of baseline total number of cocaine use days (Wald chi(2) = 3.75, df = 1, p = .05) on outcome, suggesting that the combination treatment was most effective for participants with a high baseline frequency of cocaine use. Conclusions: The results of this study supported our hypothesis that the combination of MAS-ER and topiramate would be superior to placebo in achieving 3 weeks of consecutive abstinence. These findings provide evidence that the combination of MAS-ER and topiramate is efficacious in promoting abstinence in cocaine-dependent individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available